Revaprazan Hydrochloride CAS 178307-42-1 Assay ≥99.0% API Factory High Purity
Dzina la Mankhwala: Revaprazan Hydrochloride;Revaprazan HCL
CAS: 178307-42-1
API High Quality, Commercial Production
Dzina la Chemical | Revaprazan Hydrochloride |
Mawu ofanana ndi mawu | Revaprazan HCL |
Nambala ya CAS | 178307-42-1 |
Nambala ya CAT | RF-API48 |
Stock Status | Mu Stock, Kupanga Kufikira Mazana a Kilogram |
Molecular Formula | C22H24ClFN4 |
Kulemera kwa Maselo | 398.904 |
Mtundu | Ruifu Chemical |
Kanthu | Zofotokozera |
Maonekedwe | Ufa Woyera kapena Woyera wa Crystalline |
Kusungunuka | Momasuka sungunuka mu chloroform, dichlormeth;Kusungunuka mu acetic acid;Pang'ono sungunuka methanol, DMSO;Osasungunuka mu acetone, ACN;Pafupifupi osasungunuka mu 0.1mol/L NaOH yankho.0.1mol/L HCL yankho. |
Chizindikiritso | Ayenera kuyankhidwa bwino λ max 271nm, 205nm IR |
Melting Point | 219.0 ~ 222.0 ℃ |
Kumveka ndi Mtundu | Ziyenera kukhala zomveka komanso zopanda mtundu mu dichlormeth |
Chloride | ≤8.93% |
Chidetso Chimodzi | ≤0.10% |
Zonse Zonyansa | ≤0.50% |
Kutaya pa Kuyanika | ≤0.50% |
Zotsalira pa Ignition | ≤0.10% |
Sulfate | ≤20ppm |
Arsenic | ≤10ppm |
Zitsulo Zolemera | ≤10ppm |
Kuyesa | ≥99.0% |
Test Standard | Enterprise Standard |
Kugwiritsa ntchito | Active Pharmaceutical Ingredient (API) |
Phukusi: Botolo, Aluminiyamu zojambulazo thumba, makatoni ng'oma, 25kg / Drum, kapena malinga ndi zofuna za kasitomala.
Mkhalidwe Wosungira:Sungani muzitsulo zosindikizidwa pamalo ozizira ndi owuma;Tetezani ku kuwala, chinyezi ndi tizilombo towononga.
Shanghai Ruifu Chemical Co., Ltd. ndi omwe amapanga komanso ogulitsa Revaprazan Hydrochloride (CAS: 178307-42-1) yokhala ndipamwamba kwambiri.Revaprazan Hydrochloride imachepetsa mawu a COX-2 ndipo imakhala ndi zochita zotsutsana ndi zotupa mu matenda a H. pylori.Revaprazan Hydrochloride pa matenda a duodenal chilonda, chapamimba chilonda ndi gastritis.
Revaprazan Hydrochloride (yomwe imadziwikanso kuti reversible proton pump inhibitors, potaziyamu competitive acid blockers, p-CABs) ndi m'badwo watsopano wa ma proton pump inhibitors komanso njira yokhayo yogulitsira ya potaziyamu yomwe imapezeka pamalonda pampu kapena ma asidi pampu antagonists padziko lapansi.Yopangidwa ndi kampani yaku South Korea ya Yuhan komanso yokhala ndi ufulu waumwini, GLAxoSmithKline yapeza zilolezo zachitukuko ndi malonda padziko lonse lapansi za mankhwalawo kunja kwa South Korea ndi North Korea.Mankhwalawa adavomerezedwa ndi South Korea FDA mu 2007 kuti athetse zilonda zam'mimba ndi gastritis.